The use of in vitro metabolism studies in the understanding of new drugs
References (52)
- et al.
Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography
J Chromatog
(1992) - et al.
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450
Biochem Pharm
(1985) - et al.
Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats
Biochem Pharmacol
(1983) - et al.
Cyclosporin toxicity at therapeutic blood levels and cytochrome P450 IIIA
Lancet
(1990) - et al.
Erythromycin breath test as an assay of glucorticoid inducible liver cytochromes P450: Studies in rats and patients
J Clin Invest
(1989) - et al.
Hypotensive action of Losartan, an angiotensin II antagonist, in spontaneously hypertensive rat
Hypertension
(1990) - et al.
The effects of cyclosporin A on hepatic microsomal drug metabolism in the rat
Drug Metab Dispos
(1986) - et al.
Dihydropyrimidine calcium channel blockers.3,3-carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidine carboxylic acid esters as orally effective antihypertensive agents
J Med Chem
(1991) - et al.
Metabolism of cyclosporin A II. Implication of the macrolide antibiotic inducible cytochrome P-450 3C from rabbit liver microsomes
Drug Metab Dispos
(1987) - et al.
Extrapolation from measurements in vitro to drug metabolism in vivo in man
Clinically relevant drug interaction—An overview
Nonpeptide angiotensin II receptor antagonist: The discovery of a series of N-(biphenylmethyl) imidazoles as potent, orally active antihypertensives
J Med Chem
Selective inhibition of rat hepatic microsomal cytochrome P450 I. Effect of the in vivo administration of cimetidine
J Pharm Exp Ther
Selective inhibition of rat hepatic microsomal cytochrome P-450 II. Effect of the in vitro administration of cimetidine
J Pharm Exp Ther
Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine and rat
Drug Metab Rev
Formation and disposition of EXP3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist Losartan
Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes
Xenobiotica
Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450 IIIA gene subfamily
Drug Metab Dispos
The use of animal subcellular fractions to study type II metabolism of xenobiotics
Physiological disposition of HMG-CoA-reductase inhibitor
Drug Metab Rev
The use of animal subcellular fractions to study type I metabolism of xenobiotics
Metabolism of cyclosporin A. I. Study in freshly isolated rabbit hepatocytes
Drug Metab Dispos
Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions
Drug Metab Dispos
Evaluation of cyclosporin metabolites
Br J Clin Pharmacol
The increase in urinary excretion of 6β-hydroxy-cortisol as a marker of human hepatic cytochrome P450 IIIA3 induction
Br J Clin Pharmacol
Techniques for studying drug metabolism in vitro
Cited by (28)
Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions
2010, Disease-a-MonthCitation Excerpt :Rifampin has been demonstrated to increase verapamil clearance by 32-fold.35 Calcium channel blockers inhibit the metabolism of cyclosporine.36 Diltiazem in doses as low as 10 mg increased the bioavailability of cyclosporine and resulted in the need for a lower dose to maintain efficacy or avoid toxic effects.37
Interspecies difference in liver-specific functions and biotransformation of testosterone of primary rat, porcine and human hepatocyte in an organotypical sandwich culture
2009, Toxicology LettersCitation Excerpt :The use of such a functioning human (or porcine) metabolic system will help to increase and refine the relevance of pharmacokinetic and toxicological screenings for man. An appropriate in vitro model offers the advantage of reduced complexity of the study system and allows the evaluation of intrinsic metabolic potentials or mechanisms with respect to a specific reaction (Chiu, 1993). The in vitro model has to fulfil several criteria: it has to be stable and reproducible, and hepatocytes have to be cultivated in an organotypic way, which means that the cells have to keep their ability to perform both primary metabolism and biotransformation (Cross and Bayliss, 2000).
Fetal hepatic drug elimination
1999, Pharmacology and TherapeuticsIn-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel docetaxel, tamoxifen and ifosfamide
1998, Cancer Treatment ReviewsUse of in vitro human metabolism studies in drug development. An industrial perspective
1994, Biochemical PharmacologyChemistry and enzymology: Their use in the prediction of human drug metabolism
1994, European Journal of Pharmaceutical Sciences